Companies developing medicines that contain cannabis-derived compounds say a recent federal reclassification is opening doors to new capital and potential public market listings after years of tight restrictions. The Department of Justice's decision to move FDA-approved drugs and state-sanctioned medical marijuana products out of Schedule I and toward Schedule III - the category that includes some prescription medicines and controlled substances with accepted medical uses - is being described by executives as a material change to the financing and operational environment for this segment.
Rescheduling and immediate effects on capital and banking
The Justice Department's action, which affects FDA-approved medicines and state-regulated medical marijuana products, was widely characterized by company leaders as likely to make it easier for firms to use standard banking services and to claim tax credits and deductions. Executives at three firms focused on cannabis-based therapies said the shift should reduce stigma around marijuana-based drugs and could make some mainstream investors, venture capitalists and financial institutions more willing to engage.
Ananda Pharma, which is developing a cannabidiol-based treatment for pain linked to endometriosis, said it plans to pursue private funding in the wake of the reclassification. The company aims to raise between $10 million and $20 million within approximately six months to support faster regulatory engagement in the United States and to accelerate manufacturing of its CBD product, which does not contain the psychoactive compound THC. Chief Executive Melissa Sturgess said early investor interest has already emerged, including scheduled conversations with a venture capital investor focused on endometriosis and with a sizeable U.S.-based family office.
Investor interest and broader market implications
Legal and financial advisers working with the industry said they have been told directly by venture capitalists and other investors that rescheduling will unlock capital that had largely been on the sidelines. Brett Schuman, co-chair of the cannabis practice at the Goodwin law firm, noted that his firm has heard from VCs and other investors expecting a renewed flow of investment following the policy change.
IGC Pharma, which is running mid-stage trials of a low-dose THC liquid intended to ease agitation in patients with Alzheimer's disease - a market the company has estimated could range from $1 billion to $10 billion - said uncertainty over timing and restricted banking access had previously deterred some institutions despite their interest. Ram Mukunda, IGC's chief executive, said the company is considering a $50 million fundraising toward the end of the year.
Bank covenants and the significance of reclassification
Schuman also pointed out that certain banks include covenants in loan and credit agreements that prohibit clients from investing in cannabis businesses. Some of these contractual constraints apply specifically to drugs listed as Schedule I - the federal classification previously applied to marijuana and drugs such as heroin and LSD, defined by the government as having no accepted medical use and a high potential for abuse. Moving relevant cannabis medicines to Schedule III places them alongside other controlled substances such as Tylenol with codeine, ketamine, anabolic steroids and testosterone, potentially removing a legal basis for some of those covenants.
Public listings and geographic constraints on research
Executives at Avicanna, which is advancing a cannabis-derived therapy for rare seizure disorders, said rescheduling creates clearer routes to initial public offerings on major exchanges. Avicanna's chief executive, Aras Azadian, said the Schedule I designation had made it quite difficult to conduct U.S.-based studies, prompting the company to perform much of its early research in Canada. He added that the lack of a federal pathway had been a major gating factor for entering the U.S. market without substantial investment or regulatory burden, and that rescheduling allows firms to pursue strategic entry and partnerships with local companies.
Reputational changes and clinical development costs
Executives suggested the reclassification has diminished reputational barriers that previously discouraged traditional life sciences investors from considering cannabis-derived candidates. George Hodgin, chief executive of BRC Therapeutics, said the change has already increased attention to the company's pipeline, which includes a treatment for aromatase inhibitor-induced arthralgia, a painful side effect associated with some breast cancer therapies.
Rescheduling could also reduce the operational complexity and expense of sourcing and transporting study drugs. Under Schedule I restrictions, some companies faced logistical hurdles that forced them to cultivate hemp and extract small quantities of THC or to run trials outside the United States. Mukunda described how his firm had to grow large areas of hemp to obtain the necessary THC, a process that required significant land and resources; the regulatory relaxation may simplify research designs and lower such costs.
Remaining uncertainties and limitations
Despite the anticipated benefits, executives cautioned that aligning new federal policy with a patchwork of state regulations remains a challenge for companies planning substantial U.S. investments. Differences across state laws could complicate operational planning and market entry even after rescheduling. Avicanna's Azadian emphasized that while a federal pathway now exists that did not previously, the process of deploying capital and launching U.S. programs will still require careful navigation of state-level rules.
Companies pursuing fundraising and public listings said they expect the reclassification to reduce stigma, open access to banking and tax advantages, and make it easier to run trials in the United States - but they also noted that timing, state-federal alignment and legacy contractual restrictions with lenders and investors will continue to shape how quickly capital and public market access materialize.